Natalizumab shows promise for teens with multiple sclerosis

February 22, 2013
Natalizumab shows promise for teens with multiple sclerosis
Natalizumab may be safe in pediatric multiple sclerosis patients with highly active disease, according to a small study published online Feb. 18 in JAMA Neurology.

(HealthDay)—Natalizumab may be safe in pediatric multiple sclerosis (MS) patients with highly active disease, according to a small study published online Feb. 18 in JAMA Neurology.

Barbara Kornek, M.D., from the Medical University of Vienna, and colleagues retrospectively reviewed data on 20 pediatric patients with MS who started treatment with natalizumab (300 mg every four weeks) prior to 18 years of age (mean age at initiation, 16.7 years). These patients underwent MRI as clinically indicated, despite the fact that 19 of the patients were undergoing first-line disease-modifying therapy.

The researchers found that treatment with natalizumab was associated with significant reductions in mean annualized (3.7 without treatment versus 0.4 with treatment), median Expanded Disability Status Scale scores (two without treatment versus one with treatment), and mean number of new T2/fluid-attenuated inversion recovery lesions per year (7.8 without treatment versus 0.5 with treatment). Two patients had to stop therapy due to development of high-titer neutralizing antibodies against natalizumab. Other included headaches, asthenia, infections, and hypersensitivity. Eight patients had abnormal laboratory results, with John Cunningham virus found in five of 13 patients. Relapse activity occurred in six of eight patients within six months following discontinuation of natalizumab therapy.

"Our data indicate that natalizumab may be safe and effective against MS in with breakthrough disease," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Biogen Idec, the manufacturer of .

Explore further: Remitting multiple sclerosis: Natalizumab reduces relapses and disability

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Remitting multiple sclerosis: Natalizumab reduces relapses and disability

October 5, 2011
Taking the new generation anti-inflammatory drug natalizumab for two years lowers the number of remitting multiple sclerosis patients who experience relapses and progression of disability. This is the main finding of a systematic ...

Study examines fingolimod therapy in patients with multiple sclerosis

July 2, 2012
The medication fingolimod reduced inflammatory lesion activity and reduced brain volume loss in patients with multiple sclerosis who participated in a two-year placebo-controlled clinical trial and were assessed by magnetic ...

In treated MS, early disease activity predicts poor outcome

September 27, 2012
(HealthDay)—After 15 years of follow-up, patients with relapsing-remitting multiple sclerosis (RRMS) who display disease activity despite treatment with interferon (IFN)β-1a tend to have unfavorable long-term outcomes, ...

Recommended for you

Study uncovers specialized mouse neurons that play a unique role in pain

August 17, 2017
Researchers from the National Institutes of Health have identified a class of sensory neurons (nerve cells that electrically send and receive messages between the body and brain) that can be activated by stimuli as precise ...

Scientists discover powerful potential pain reliever

August 16, 2017
A team of scientists led by chemists Stephen Martin and James Sahn at The University of Texas at Austin have discovered what they say is a powerful pain reliever that acts on a previously unknown pain pathway. The synthetic ...

Scientists use magnetic fields to remotely stimulate brain—and control body movements

August 16, 2017
Scientists have used magnetism to activate tiny groups of cells in the brain, inducing bodily movements that include running, rotating and losing control of the extremities—an achievement that could lead to advances in ...

Scientists give star treatment to lesser-known cells crucial for brain development

August 16, 2017
After decades of relative neglect, star-shaped brain cells called astrocytes are finally getting their due. To gather insight into a critical aspect of brain development, a team of scientists examined the maturation of astrocytes ...

The nerve-guiding 'labels' that may one day help re-establish broken nervous connections

August 16, 2017
Scientists have identified a large group of biological 'labels' that guide nerves to ensure they make the correct connections and control different parts of the body. Although their research was conducted with fruit flies, ...

Navigation and spatial memory—new brain region identified to be involved

August 16, 2017
Navigation in mammals including humans and rodents depends on specialized neural networks that encode the animal's location and trajectory in the environment, serving essentially as a GPS, findings that led to the 2014 Nobel ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.